As bispecific antibodies gain prominence for their revolutionary therapeutic ... ALG.APV-527 is being evaluated in a Phase 1 trial for solid tumors likely to express the tumor antigen 5T4. Tumor types ...

MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

Further testing revealed that the patient carried antibodies against the M antigen with a mild IgG reactivity after using the ...

Scientists have created a novel technology for developing antibody (M6P) conjugates without enzyme modification in vitro, ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector ...

AI is finding its way into every corner of biotech and pharmaceutical research, but like other industries, it's never quite ...

Laboratory testing must be done before donated blood ever makes it to the hospital. Tests are conducted to make sure donated ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today ...